Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADCY10 | Q96PN6 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343956 | 0.87 | FPR1 (0.39) | FPR1MEN1KMT2AFPR2ALDH1A1 | |
| SCHEMBL29339894 | 0.86 | ADCY10 (0.37) | ADCY10HPGDALDH1A1 | |
| SCHEMBL29339879 | 0.84 | ALDH1A1 (0.36) | MEN1KMT2AADCY10ALDH1A1 | |
| SCHEMBL29339780 | 0.82 | ADCY10 (0.44) | ADCY10ALDH1A1 | |
| SCHEMBL29343971 | 0.82 | EED (0.41) | FPR1MEN1KMT2AHTTFPR2 | |
| SCHEMBL29340216 | 0.76 | ADCY10 (0.40) | FPR1ADCY10HTTALDH1A1 | |
| SCHEMBL29342733 | 0.74 | ALDH1A1 (0.36) | MEN1KMT2AADCY10HPGDALDH1A1 | |
| SCHEMBL29339982 | 0.74 | IL2 (0.33) | — | |
| SCHEMBL29342685 | 0.73 | EPHX2 (0.37) | MEN1KMT2AHPGDHTTALDH1A1 | |
| SCHEMBL29342218 | 0.71 | MEN1 (0.42) | MEN1PKMKMT2AADCY10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | MTNR1A 3091/4885MTNR1B 2460/4885FPR1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.